Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
VERTEX PHARMACEUTICALS INC / MA | Director | Deferred Stock Units | 5,609 | $2.43 M | $432.99 | May 1, 2022 | Direct |
AMICUS THERAPEUTICS, INC. | Director | Common Stock | 71,136 | $711 K | $10.00 | Jun 6, 2024 | Direct |
VERTEX PHARMACEUTICALS INC / MA | Director | Stock Option (Right to Buy) | 3,481 | $444 K | $127.54 | May 1, 2023 | Direct |
NOVAVAX INC | Director | Stock Option (Right to Buy) | 15,630 | $248 K | $15.86 | Jun 12, 2024 | Direct |
NOVAVAX INC | Director | Common Stock | 10,470 | $146 K | $13.90 | Jun 12, 2024 | Direct |
NOVAVAX INC | Director | Restricted Stock Units | 10,420 | $145 K | $13.90 | Jun 12, 2024 | Direct |
VERTEX PHARMACEUTICALS INC / MA | Director | Common Stock | 178 | $74.6 K | $419.07 | May 1, 2022 | Direct |
AMICUS THERAPEUTICS, INC. | Director | Stock Options (right to buy) | 42,467 | Jun 6, 2024 | Direct |